世界の肺がん液体生検市場 – 2030 年までの業界動向と予測

 肺がん液体生検市場の分析と規模

国立がん研究所によると、肺がんは米国における死亡原因の第 1 位です。肺がんは世界で 2 番目に多く診断されるがんであり、がんによる死亡原因の第 1 位で、2012 年には 180 万人が新たに肺がんと診断されたと推定されています。現在、肺がんの 5 年生存率は 17% ～ 22% ですが、診断の段階によって生存率は異なります。リキッド バイオプシーは肺がんの診断において大きな可能性を秘めています。

Data Bridge Market Research の分析によると、2022 年に 3 億米ドルだった肺がん液体生検市場は、2023 年から 2030 年の予測期間中に 21% の CAGR で成長し、2030 年には 13 億 8 千万米ドルに達すると予想されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Research がまとめた市場レポートには、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

肺がん液体生検市場の範囲とセグメンテーション      

Market Definition

Liquid biopsy is a non-invasive alternative to surgical biopsies that aids in detecting molecular biomarkers. Liquid biopsy eliminates the need for costly invasive procedures by allowing doctors to detect diseases and make decisions using a blood sample from the patient. Liquid biopsy is a non-invasive alternative to surgical biopsies for detecting molecular biomarkers. Liquid biopsy is an essential component of precision medicine, with enormous diagnostic and treatment implications for oncology that can result in radical changes in clinical practice. It allows doctors to detect the onset of a disease or tumour by analyzing a simple blood sample. The presence of cancer cells or traces of RNA or DNA from cancer cells in the blood helps to determine the best course of treatment for a patient.

Global Lung Cancer Liquid Biopsy Market Dynamics

Drivers

• Rising incidence of lung cancer

The rising incidence of lung cancer is one of the primary drivers of the lung cancer liquid biopsy market. Lung cancer is the leading cause of cancer death worldwide. The main causes of the rising prevalence of lung cancer are smoking, passive smoking, air pollution, and genetic abnormalities. These are the certain reasons which boost the growth of the market.

• Rising use of personalized medicine

The liquid biopsy results can help physicians determine the treatment pattern for patients. These benefits are supplementing vendors' focus on providing a personalized treatment plan to lung cancer patients. Personalized medicine ensures that medications are targeted and effective. One of the key factors expected to positively impact the lung cancer liquid biopsy market during the forecast period.

Opportunities

• Growing awareness of patient and health-care professional

Growing patient and health-care professional awareness have increased the number of diagnosed lung cancer cases in Asia, particularly in China and India. The factors such as an increase in the number of reported lung cancer cases and significant investments in R&D of effective treatment alternatives in the region, North America is expected to dominate the global lung cancer liquid biopsy market in the near future.

Restraints/Challenges

• Lung cancer misdiagnosis

Lung cancer misdiagnosis, inadequate tumour sampling, and delayed diagnoses are also common due to limitations of the tissue biopsy will obstruct the market's growth rate.

This lung cancer liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the lung cancer liquid biopsy market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Lung Cancer Liquid Biopsy Market

COVID-19 has infected approximately 532 million people worldwide. According to the most recent World meters’ statistics, the global death toll has reached 6,311,594. (as of May 31, 2022). The number is still growing, and the duration of the pandemic remains unknown. The impact of the COVID-19 pandemic on societies and economies around the world cannot be overstated. During the forecast period, the COVID-19 global pandemic has slowed the growth rate of the lung cancer liquid biopsy market.

Global Lung Cancer Liquid Biopsy Market Scope

The lung cancer liquid biopsy market is segmented on the basis of biomarker type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Biomarker Type

• CTC (Circulating Tumor Cells)
• ctDNA (Circulating tumor DNA)
• Exosomes and RNA

 Application

• Small Cell Lung Cancer
• Non-Small Cell Lung Cancer

 End-User

• Diagnostic and Imaging Centres
• Hospitals
• Academic and Research Centers
• Others

Lung Cancer Liquid Biopsy Market Regional Analysis/Insights

The lung cancer liquid biopsy market is analyzed and market size insights and trends are provided by country, biomarker type, application and end-user as referenced above.

The countries covered in the lung cancer liquid biopsy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the lung cancer liquid biopsy market because of the presence of well-developed healthcare infrastructure and favourable reimbursement policies in the region.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the high CAGR in the forecast period and due to large patient pool in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The lung cancer liquid biopsy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer liquid biopsy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer liquid biopsy market. The data is available for historic period 2011-2021.

Competitive Landscape and Lung Cancer Liquid Biopsy Market Share Analysis

The lung cancer liquid biopsy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer liquid biopsy market.

Some of the major players operating in the lung cancer liquid biopsy market are:

• Eurofins Scientific (Luxembourg)
• MDxHealth (Belgium)
• CareDx (U.S.)
• Immucor (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• Menarini Silicon Biosystems (U.S.)
• QIAGEN (Germany)
• Guardant Health (U.S.)
• Exact Sciences Corporation (U.S.)
• Myriad Genetics, Inc. (U.S.)
• LungLife AI, Inc. (U.S.)
• Bio-Rad Laboratories, Inc. (U.S.)
• Agilent Technologies Inc. (U.S.)
• Natera, Inc. (U.S.)
• CARDIFF ONCOLOGY, INC. (U.S.)
• Exosome Diagnostics Inc. (U.S.)
• Illumina, Inc. (U.S.)
• Genomic Health Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)

Research Methodology: Global Lung Cancer Liquid Biopsy Market

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせ内容をドロップダウンしてください。

DBMR リサーチ チームが使用する主要なリサーチ手法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これ以外にも、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。リサーチ手法について詳しくは、お問い合わせフォームから当社の業界の専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合ったデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、再開発市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社を必要なだけ追加し、必要な形式とデータ スタイルでデータを作成できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクトブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。 

SKU-56645